Several articles have demonstrated that administration of CAI, oroxylin A, or wogonoside could alleviate the severity of experimental colitis, suppress the mucosal inflammation, which might be attributed to its inhibition of NF-κB and NLRP3 inflammasome activation (93, 94). Here, NLRP3 is linked to colitis.